Explore
Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Read More
Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances
Read More
Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Pipeline Updates
AN2 Therapeutics Reports Q1 2026 Financial Results and Pipeline Updates
Read More
Trendline
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Lantern Pharma to Announce Q1 2026 Financial Results Amid AI-Driven Oncology Developments
Read More
Trendline
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Atara Biotherapeutics Reports Significant Revenue Decline and Operational Updates for Q1 2026
Read More
Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Read More
Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Read More
Trendline
Anteris Technologies Reports Q1 2026 Financial Results with Increased Net Loss
Anteris Technologies Reports Q1 2026 Financial Results with Increased Net Loss
Read More
Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026
Verastem Oncology to Present at Key Investor Conferences in May 2026
Read More
Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Read More
Trendline
Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates
Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates
Read More
Trendline
enGene Faces Stock Plunge Amid Declining Response Rates in Bladder Cancer Therapy
enGene Faces Stock Plunge Amid Declining Response Rates in Bladder Cancer Therapy
Read More
